IMU & CHM Should Merge

CHM and IMU Should Merge & Leadership Must Change.

Both of which have been royally screwed by Hopper.

A merger between the two presents a compelling opportunity to create a stronger, more focused biotech company capable of delivering real value to shareholders, BUT only if it's accompanied by urgent leadership change.

Both companies are operating in a high-risk, high-reward sector. CHM’s pipeline, particularly its CDH17CAR-T cell therapy, is showing promising progress in early trials. IMU, while boasting a broader pipeline, has been hampered by bloated executive costs, questionable capital management, and eroded investor confidence.

By merging operational synergies could be realised, consolidating resources, reducing duplicated overheads, and improving clinical trial efficiency & a stronger market position could be established, combining CHM’s cell therapy innovation with IMU’s immunotherapy platform.

More importantly improved capital discipline needs to be enforced, with investor focus returning to science and outcomes, not executive excess. Hopper & Chong have overseen sustained share price erosion and controversial capital raises, often viewed as dilutive and poorly timed. With Hopper leading similar destruction at CHM.

Chong draws a staggering $2.5 million per year, far above industry norms for a company of this size and performance. This compensation is unjustifiable given ongoing shareholder losses and the company’s current financial position. Executive remuneration should reflect value delivered, not simply tenure.

IMO the merged entity should be led by:
Dr. Rebecca McQualter as CEO. CHM’s current leader, known for prudent financial management, strategic agility, and clear communication with shareholders.
Professor Miles Prince as Chairman. A respected clinical researcher with deep understanding of the science and a track record of prioritising both patient outcomes and shareholder value.

Investors from both companies deserve accountability, a leaner operation, and a renewed focus on delivering clinical and financial results.

The science is promising. The structure is not. It’s time to fix that.